SG Americas Securities LLC Decreases Stock Holdings in Repligen Corporation $RGEN

SG Americas Securities LLC reduced its position in shares of Repligen Corporation (NASDAQ:RGEN) by 62.1% in the first quarter, Holdings Channel reports. The fund owned 5,644 shares of the biotechnology company’s stock after selling 9,249 shares during the quarter. SG Americas Securities LLC’s holdings in Repligen were worth $665,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Measured Wealth Private Client Group LLC bought a new stake in Repligen in the third quarter worth $29,000. Bayforest Capital Ltd purchased a new position in shares of Repligen in the 4th quarter worth $32,000. Rachor Investment Advisory Services LLC bought a new stake in shares of Repligen in the 4th quarter worth about $33,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen in the 4th quarter worth about $36,000. Finally, Farther Finance Advisors LLC raised its position in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Trading Down 0.2%

Shares of RGEN traded down $0.35 during trading hours on Tuesday, reaching $141.11. 12,680 shares of the company traded hands, compared to its average volume of 980,766. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77. The stock’s fifty day moving average price is $124.38 and its 200 day moving average price is $134.49. The firm has a market cap of $7.96 billion, a price-to-earnings ratio of 156.52, a PEG ratio of 2.74 and a beta of 1.06. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.25 million during the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Canaccord Genuity Group decreased their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research report on Monday, April 20th. Barclays lifted their target price on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the company a “buy” rating in a research report on Friday, April 17th. Finally, Royal Bank Of Canada assumed coverage on Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $165.00.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.60% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.